Please assess the completion status of the following clinical trial:

Trial Title: PNEUMOCELL - Conjugated Pneumococcal Vaccination in Patients With Immunoglobulin G-deficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Immunoglobulin gamma-deficiency: Immunoglobulin gamma 1-deficiency \< 2,8 g/L and/or Immunoglobulin gamma 2-deficiency \< 1,15 g/L~* Age 18-65~Exclusion Criteria:~* Immunoglobulin gamma-substitution for 6 months prior to study inclusion~* Prevenar7 or Prevenar13 given prior to study inclusion.~* Pneumovax given during a 2 year period prior to study inclusion~* Pregnancy or planning to become pregnant during the study period (4 weeks)~* Taking part in another clinical study involving drugs or vaccinations during the study period (4 weeks).~* Taking systemic steroids, Non steroidal anti inflammatory drugs (NSAID) or immunosuppressive drugs.~* Being allergic to any substance in the vaccine.~* Acute and ongoing disease with high fever.~* Thrombocytopenia (\< 100x109/L).~* Coagulopathy~* Breastfeeding a baby~* The healthy controls should not have any disease with effects on the immune-system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- IgG-deficient patients (Type: ACTIVE_COMPARATOR): Prevenar13
- Healthy controls (Type: ACTIVE_COMPARATOR): Prevenar13

Based on this trial design, predict the completion outcome and termination type (if applicable).